Achaogen Stock

Achaogen Net Debt / EBITDA

Delisted

The Net Debt to EBITDA of Achaogen (AKAOQ) as of Aug 13, 2026 is -0.27. In the previous year, Net Debt to EBITDA was -0.25 — a change of 8.22% (lower).

Net Debt / EBITDA

-0.27

YoY

8.22%

Last updated:

Net Debt to EBITDA of Achaogen is 2026 -0.27 . Net Debt to EBITDA of Achaogen was 2025 -0.25 . It decreases by 8.22% lower compared to the previous year.
Access this data via the Eulerpool API

Achaogen Stock analysis

What does Achaogen do? Achaogen Inc is an innovative biotechnology company specializing in the development of antibiotics for the treatment of life-threatening infectious diseases. The company's business model is based on research and development of new antibiotics, aiming to improve medical care for patients with infections. Achaogen was founded in 2002 by a team of researchers and professionals in the biotechnology industry and has developed several products for the treatment of diseases such as pneumonia, urinary tract infections, and bloodstream infections. The company's main divisions include Plazomicin, Zemdri, and C-Scape, which are antibiotics targeting different types of infections. Achaogen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Achaogen stock

Net Debt to EBITDA of Achaogen is -0.27 in 2026.

Net Debt to EBITDA of Achaogen changed from -0.25 to -0.27, representing a 8.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Achaogen since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Achaogen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Achaogen

All Key Metrics — Achaogen